The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics is set to participate in the Jefferies Global Healthcare Conference in New York, where the company will provide an update on its investigational pipeline and corporate strategy.
The event highlights Allogene Therapeutics' continued engagement with the investment community and reinforces its commitment to advancing allogeneic cell therapy platforms. Webcast information is available in the Investors section of the company's website.
Allogene Therapeutics recently shared pipeline and corporate strategy updates during the TD Cowen Oncology Innovation Summit webcast. The company also introduced ALLO-329, a next-generation cell therapy candidate for autoimmune diseases, with an approach aimed at reducing lymphodepletion risks. These developments reflect Allogene’s ongoing efforts to advance its clinical portfolio.